Abstract
Rates of confirmed and severe, as well as nocturnal, hypoglycemia are generally lower with insulin glargine U-300 than insulin glargine U-100, thereby reducing an important concern of providers and patients regarding insulin therapy. Although a higher dose of insulin glargine U-300 than U-100 is required in most patients, the observed increase in body weight is small and less than with insulin glargine U-100.
MeSH terms
-
Adult
-
Aged
-
Biomarkers / blood
-
Blood Glucose / analysis
-
Body Mass Index
-
Body Weight
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Female
-
Glycated Hemoglobin / metabolism
-
Humans
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / therapeutic use*
-
Injections, Subcutaneous
-
Insulin Glargine / administration & dosage
-
Insulin Glargine / therapeutic use*
-
Male
-
Middle Aged
-
Treatment Outcome
Substances
-
Biomarkers
-
Blood Glucose
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Insulin Glargine